Global Genetic Obesity Drug Supply, Demand and Key Producers, 2023-2029

Description

The global Genetic Obesity Drug market size is expected to reach $ 4186.4 million by 2029, rising at a market growth of 6.3% CAGR during the forecast period (2023-2029).

The global genetic obesity drug market refers to the market for medications and therapies used to treat obesity caused by genetic factors. Genetic obesity is a complex condition that arises from various genetic mutations and alterations, leading to an increased risk of excessive weight gain and difficulty in losing weight.

The treatment of genetic obesity focuses on managing weight gain and associated health issues. While lifestyle modifications such as diet and exercise are important in managing obesity, genetic obesity may require additional targeted interventions. Currently, there is ongoing research and development in the field of genetic obesity drugs, with the aim of developing medications that can directly address the underlying genetic causes of obesity.

The global genetic obesity drug market is influenced by factors such as the increasing prevalence of obesity, advancements in genetic research, and the need for personalized treatment options. However, it’s important to note that the market for genetic obesity drugs is still in its early stages, and there are currently limited approved medications specifically targeted towards genetic obesity.

Geographically, the market for genetic obesity drugs is expected to witness growth across regions with a high prevalence of obesity, such as North America, Europe, and the Asia Pacific. These regions have well-established healthcare infrastructure and research capabilities, which contribute to advancements in genetic obesity treatment options.

Key players in the global genetic obesity drug market include pharmaceutical companies, biotechnology firms, and research institutions. These entities are actively involved in research and development efforts to identify novel drug targets, explore gene-based therapies, and conduct clinical trials.

It’s important to note that the development and approval of drugs for genetic obesity are complex processes that involve rigorous testing, regulatory approvals, and extensive research. The timeline for the availability of specific genetic obesity drugs may vary based on the stage of development and regulatory requirements.

In summary, the global genetic obesity drug market is in its early stages of development. Although there are currently limited approved medications targeted towards genetic obesity, ongoing research and advancements in genetic understanding hold promise for the future. As research progresses and personalized treatment approaches emerge, the market for genetic obesity drugs may expand, offering new treatment options for individuals affected by genetic forms of obesity.

Obesity, a condition in which body fat levels are elevated to extreme extent, is a common disorder. Obesity is a condition caused by the lower levels of the metabolism rate.The current advancement in Genetic Obesity Drugs in rapidly recovering the appetite inhibiting hormone level in the body is anticipated to increase the adoption of Genetic obesity drugs in physicians.

This report studies the global Genetic Obesity Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Genetic Obesity Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Genetic Obesity Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Genetic Obesity Drug total market, 2018-2029, (USD Million)
Global Genetic Obesity Drug total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Genetic Obesity Drug total market, key domestic companies and share, (USD Million)
Global Genetic Obesity Drug revenue by player and market share 2018-2023, (USD Million)
Global Genetic Obesity Drug total market by Type, CAGR, 2018-2029, (USD Million)
Global Genetic Obesity Drug total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Genetic Obesity Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Inc., Sanofi., Tonghua Dongbao Pharmaceutical Co., Ltd., Biocon., Adocia, GlaxoSmithKline Plc., Novo Nordisk A/S., Oramed Pharmaceuticals, Inc and Wockhardt., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Genetic Obesity Drug market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Genetic Obesity Drug Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Genetic Obesity Drug Market, Segmentation by Type
    Sibutramine
    Orlistat
    Sympathomimetic Drugs
    Receptors Antagonists
    Others

Global Genetic Obesity Drug Market, Segmentation by Application
    Hospitals Pharmacy
    Retail Pharmacy
    Online Pharmacy
    Others

Companies Profiled:
    Pfizer, Inc.
    Sanofi.
    Tonghua Dongbao Pharmaceutical Co., Ltd.
    Biocon.
    Adocia
    GlaxoSmithKline Plc.
    Novo Nordisk A/S.
    Oramed Pharmaceuticals, Inc
    Wockhardt.
    Eli Lilly and Company.
    Merck & Co., Inc.
    Julphar.
    Bristol-Myers Squibb Company.

Key Questions Answered
1. How big is the global Genetic Obesity Drug market?
2. What is the demand of the global Genetic Obesity Drug market?
3. What is the year over year growth of the global Genetic Obesity Drug market?
4. What is the total value of the global Genetic Obesity Drug market?
5. Who are the major players in the global Genetic Obesity Drug market?

Table of Contents

1 Supply Summary
    1.1 Genetic Obesity Drug Introduction
    1.2 World Genetic Obesity Drug Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Genetic Obesity Drug Total Market by Region (by Headquarter Location)
        1.3.1 World Genetic Obesity Drug Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Genetic Obesity Drug Market Size (2018-2029)
        1.3.3 China Genetic Obesity Drug Market Size (2018-2029)
        1.3.4 Europe Genetic Obesity Drug Market Size (2018-2029)
        1.3.5 Japan Genetic Obesity Drug Market Size (2018-2029)
        1.3.6 South Korea Genetic Obesity Drug Market Size (2018-2029)
        1.3.7 ASEAN Genetic Obesity Drug Market Size (2018-2029)
        1.3.8 India Genetic Obesity Drug Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Genetic Obesity Drug Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Genetic Obesity Drug Major Market Trends

2 Demand Summary
    2.1 World Genetic Obesity Drug Consumption Value (2018-2029)
    2.2 World Genetic Obesity Drug Consumption Value by Region
        2.2.1 World Genetic Obesity Drug Consumption Value by Region (2018-2023)
        2.2.2 World Genetic Obesity Drug Consumption Value Forecast by Region (2024-2029)
    2.3 United States Genetic Obesity Drug Consumption Value (2018-2029)
    2.4 China Genetic Obesity Drug Consumption Value (2018-2029)
    2.5 Europe Genetic Obesity Drug Consumption Value (2018-2029)
    2.6 Japan Genetic Obesity Drug Consumption Value (2018-2029)
    2.7 South Korea Genetic Obesity Drug Consumption Value (2018-2029)
    2.8 ASEAN Genetic Obesity Drug Consumption Value (2018-2029)
    2.9 India Genetic Obesity Drug Consumption Value (2018-2029)

3 World Genetic Obesity Drug Companies Competitive Analysis
    3.1 World Genetic Obesity Drug Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Genetic Obesity Drug Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Genetic Obesity Drug in 2022
        3.2.3 Global Concentration Ratios (CR8) for Genetic Obesity Drug in 2022
    3.3 Genetic Obesity Drug Company Evaluation Quadrant
    3.4 Genetic Obesity Drug Market: Overall Company Footprint Analysis
        3.4.1 Genetic Obesity Drug Market: Region Footprint
        3.4.2 Genetic Obesity Drug Market: Company Product Type Footprint
        3.4.3 Genetic Obesity Drug Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Genetic Obesity Drug Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Genetic Obesity Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Genetic Obesity Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Genetic Obesity Drug Consumption Value Comparison
        4.2.1 United States VS China: Genetic Obesity Drug Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Genetic Obesity Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Genetic Obesity Drug Companies and Market Share, 2018-2023
        4.3.1 United States Based Genetic Obesity Drug Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Genetic Obesity Drug Revenue, (2018-2023)
    4.4 China Based Companies Genetic Obesity Drug Revenue and Market Share, 2018-2023
        4.4.1 China Based Genetic Obesity Drug Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Genetic Obesity Drug Revenue, (2018-2023)
    4.5 Rest of World Based Genetic Obesity Drug Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Genetic Obesity Drug Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Genetic Obesity Drug Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Genetic Obesity Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Sibutramine
        5.2.2 Orlistat
        5.2.3 Sympathomimetic Drugs
        5.2.4 Receptors Antagonists
        5.2.5 Others
    5.3 Market Segment by Type
        5.3.1 World Genetic Obesity Drug Market Size by Type (2018-2023)
        5.3.2 World Genetic Obesity Drug Market Size by Type (2024-2029)
        5.3.3 World Genetic Obesity Drug Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Genetic Obesity Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hospitals Pharmacy
        6.2.2 Retail Pharmacy
        6.2.3 Online Pharmacy
        6.2.4 Others
        6.2.5 Others
    6.3 Market Segment by Application
        6.3.1 World Genetic Obesity Drug Market Size by Application (2018-2023)
        6.3.2 World Genetic Obesity Drug Market Size by Application (2024-2029)
        6.3.3 World Genetic Obesity Drug Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Pfizer, Inc.
        7.1.1 Pfizer, Inc. Details
        7.1.2 Pfizer, Inc. Major Business
        7.1.3 Pfizer, Inc. Genetic Obesity Drug Product and Services
        7.1.4 Pfizer, Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Pfizer, Inc. Recent Developments/Updates
        7.1.6 Pfizer, Inc. Competitive Strengths & Weaknesses
    7.2 Sanofi.
        7.2.1 Sanofi. Details
        7.2.2 Sanofi. Major Business
        7.2.3 Sanofi. Genetic Obesity Drug Product and Services
        7.2.4 Sanofi. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Sanofi. Recent Developments/Updates
        7.2.6 Sanofi. Competitive Strengths & Weaknesses
    7.3 Tonghua Dongbao Pharmaceutical Co., Ltd.
        7.3.1 Tonghua Dongbao Pharmaceutical Co., Ltd. Details
        7.3.2 Tonghua Dongbao Pharmaceutical Co., Ltd. Major Business
        7.3.3 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product and Services
        7.3.4 Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Developments/Updates
        7.3.6 Tonghua Dongbao Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
    7.4 Biocon.
        7.4.1 Biocon. Details
        7.4.2 Biocon. Major Business
        7.4.3 Biocon. Genetic Obesity Drug Product and Services
        7.4.4 Biocon. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Biocon. Recent Developments/Updates
        7.4.6 Biocon. Competitive Strengths & Weaknesses
    7.5 Adocia
        7.5.1 Adocia Details
        7.5.2 Adocia Major Business
        7.5.3 Adocia Genetic Obesity Drug Product and Services
        7.5.4 Adocia Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Adocia Recent Developments/Updates
        7.5.6 Adocia Competitive Strengths & Weaknesses
    7.6 GlaxoSmithKline Plc.
        7.6.1 GlaxoSmithKline Plc. Details
        7.6.2 GlaxoSmithKline Plc. Major Business
        7.6.3 GlaxoSmithKline Plc. Genetic Obesity Drug Product and Services
        7.6.4 GlaxoSmithKline Plc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 GlaxoSmithKline Plc. Recent Developments/Updates
        7.6.6 GlaxoSmithKline Plc. Competitive Strengths & Weaknesses
    7.7 Novo Nordisk A/S.
        7.7.1 Novo Nordisk A/S. Details
        7.7.2 Novo Nordisk A/S. Major Business
        7.7.3 Novo Nordisk A/S. Genetic Obesity Drug Product and Services
        7.7.4 Novo Nordisk A/S. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 Novo Nordisk A/S. Recent Developments/Updates
        7.7.6 Novo Nordisk A/S. Competitive Strengths & Weaknesses
    7.8 Oramed Pharmaceuticals, Inc
        7.8.1 Oramed Pharmaceuticals, Inc Details
        7.8.2 Oramed Pharmaceuticals, Inc Major Business
        7.8.3 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product and Services
        7.8.4 Oramed Pharmaceuticals, Inc Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Oramed Pharmaceuticals, Inc Recent Developments/Updates
        7.8.6 Oramed Pharmaceuticals, Inc Competitive Strengths & Weaknesses
    7.9 Wockhardt.
        7.9.1 Wockhardt. Details
        7.9.2 Wockhardt. Major Business
        7.9.3 Wockhardt. Genetic Obesity Drug Product and Services
        7.9.4 Wockhardt. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 Wockhardt. Recent Developments/Updates
        7.9.6 Wockhardt. Competitive Strengths & Weaknesses
    7.10 Eli Lilly and Company.
        7.10.1 Eli Lilly and Company. Details
        7.10.2 Eli Lilly and Company. Major Business
        7.10.3 Eli Lilly and Company. Genetic Obesity Drug Product and Services
        7.10.4 Eli Lilly and Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 Eli Lilly and Company. Recent Developments/Updates
        7.10.6 Eli Lilly and Company. Competitive Strengths & Weaknesses
    7.11 Merck & Co., Inc.
        7.11.1 Merck & Co., Inc. Details
        7.11.2 Merck & Co., Inc. Major Business
        7.11.3 Merck & Co., Inc. Genetic Obesity Drug Product and Services
        7.11.4 Merck & Co., Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Merck & Co., Inc. Recent Developments/Updates
        7.11.6 Merck & Co., Inc. Competitive Strengths & Weaknesses
    7.12 Julphar.
        7.12.1 Julphar. Details
        7.12.2 Julphar. Major Business
        7.12.3 Julphar. Genetic Obesity Drug Product and Services
        7.12.4 Julphar. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.12.5 Julphar. Recent Developments/Updates
        7.12.6 Julphar. Competitive Strengths & Weaknesses
    7.13 Bristol-Myers Squibb Company.
        7.13.1 Bristol-Myers Squibb Company. Details
        7.13.2 Bristol-Myers Squibb Company. Major Business
        7.13.3 Bristol-Myers Squibb Company. Genetic Obesity Drug Product and Services
        7.13.4 Bristol-Myers Squibb Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.13.5 Bristol-Myers Squibb Company. Recent Developments/Updates
        7.13.6 Bristol-Myers Squibb Company. Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Genetic Obesity Drug Industry Chain
    8.2 Genetic Obesity Drug Upstream Analysis
    8.3 Genetic Obesity Drug Midstream Analysis
    8.4 Genetic Obesity Drug Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Genetic Obesity Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Genetic Obesity Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Genetic Obesity Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Genetic Obesity Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Genetic Obesity Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Genetic Obesity Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Genetic Obesity Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Genetic Obesity Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Genetic Obesity Drug Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Genetic Obesity Drug Players in 2022
    Table 12. World Genetic Obesity Drug Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Genetic Obesity Drug Company Evaluation Quadrant
    Table 14. Head Office of Key Genetic Obesity Drug Player
    Table 15. Genetic Obesity Drug Market: Company Product Type Footprint
    Table 16. Genetic Obesity Drug Market: Company Product Application Footprint
    Table 17. Genetic Obesity Drug Mergers & Acquisitions Activity
    Table 18. United States VS China Genetic Obesity Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Genetic Obesity Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Genetic Obesity Drug Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Genetic Obesity Drug Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Genetic Obesity Drug Revenue Market Share (2018-2023)
    Table 23. China Based Genetic Obesity Drug Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Genetic Obesity Drug Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Genetic Obesity Drug Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Genetic Obesity Drug Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Genetic Obesity Drug Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Genetic Obesity Drug Revenue Market Share (2018-2023)
    Table 29. World Genetic Obesity Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Genetic Obesity Drug Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Genetic Obesity Drug Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Genetic Obesity Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Genetic Obesity Drug Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Genetic Obesity Drug Market Size by Application (2024-2029) & (USD Million)
    Table 35. Pfizer, Inc. Basic Information, Area Served and Competitors
    Table 36. Pfizer, Inc. Major Business
    Table 37. Pfizer, Inc. Genetic Obesity Drug Product and Services
    Table 38. Pfizer, Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Pfizer, Inc. Recent Developments/Updates
    Table 40. Pfizer, Inc. Competitive Strengths & Weaknesses
    Table 41. Sanofi. Basic Information, Area Served and Competitors
    Table 42. Sanofi. Major Business
    Table 43. Sanofi. Genetic Obesity Drug Product and Services
    Table 44. Sanofi. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Sanofi. Recent Developments/Updates
    Table 46. Sanofi. Competitive Strengths & Weaknesses
    Table 47. Tonghua Dongbao Pharmaceutical Co., Ltd. Basic Information, Area Served and Competitors
    Table 48. Tonghua Dongbao Pharmaceutical Co., Ltd. Major Business
    Table 49. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Product and Services
    Table 50. Tonghua Dongbao Pharmaceutical Co., Ltd. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Tonghua Dongbao Pharmaceutical Co., Ltd. Recent Developments/Updates
    Table 52. Tonghua Dongbao Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
    Table 53. Biocon. Basic Information, Area Served and Competitors
    Table 54. Biocon. Major Business
    Table 55. Biocon. Genetic Obesity Drug Product and Services
    Table 56. Biocon. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Biocon. Recent Developments/Updates
    Table 58. Biocon. Competitive Strengths & Weaknesses
    Table 59. Adocia Basic Information, Area Served and Competitors
    Table 60. Adocia Major Business
    Table 61. Adocia Genetic Obesity Drug Product and Services
    Table 62. Adocia Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Adocia Recent Developments/Updates
    Table 64. Adocia Competitive Strengths & Weaknesses
    Table 65. GlaxoSmithKline Plc. Basic Information, Area Served and Competitors
    Table 66. GlaxoSmithKline Plc. Major Business
    Table 67. GlaxoSmithKline Plc. Genetic Obesity Drug Product and Services
    Table 68. GlaxoSmithKline Plc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. GlaxoSmithKline Plc. Recent Developments/Updates
    Table 70. GlaxoSmithKline Plc. Competitive Strengths & Weaknesses
    Table 71. Novo Nordisk A/S. Basic Information, Area Served and Competitors
    Table 72. Novo Nordisk A/S. Major Business
    Table 73. Novo Nordisk A/S. Genetic Obesity Drug Product and Services
    Table 74. Novo Nordisk A/S. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. Novo Nordisk A/S. Recent Developments/Updates
    Table 76. Novo Nordisk A/S. Competitive Strengths & Weaknesses
    Table 77. Oramed Pharmaceuticals, Inc Basic Information, Area Served and Competitors
    Table 78. Oramed Pharmaceuticals, Inc Major Business
    Table 79. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Product and Services
    Table 80. Oramed Pharmaceuticals, Inc Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Oramed Pharmaceuticals, Inc Recent Developments/Updates
    Table 82. Oramed Pharmaceuticals, Inc Competitive Strengths & Weaknesses
    Table 83. Wockhardt. Basic Information, Area Served and Competitors
    Table 84. Wockhardt. Major Business
    Table 85. Wockhardt. Genetic Obesity Drug Product and Services
    Table 86. Wockhardt. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. Wockhardt. Recent Developments/Updates
    Table 88. Wockhardt. Competitive Strengths & Weaknesses
    Table 89. Eli Lilly and Company. Basic Information, Area Served and Competitors
    Table 90. Eli Lilly and Company. Major Business
    Table 91. Eli Lilly and Company. Genetic Obesity Drug Product and Services
    Table 92. Eli Lilly and Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. Eli Lilly and Company. Recent Developments/Updates
    Table 94. Eli Lilly and Company. Competitive Strengths & Weaknesses
    Table 95. Merck & Co., Inc. Basic Information, Area Served and Competitors
    Table 96. Merck & Co., Inc. Major Business
    Table 97. Merck & Co., Inc. Genetic Obesity Drug Product and Services
    Table 98. Merck & Co., Inc. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 99. Merck & Co., Inc. Recent Developments/Updates
    Table 100. Merck & Co., Inc. Competitive Strengths & Weaknesses
    Table 101. Julphar. Basic Information, Area Served and Competitors
    Table 102. Julphar. Major Business
    Table 103. Julphar. Genetic Obesity Drug Product and Services
    Table 104. Julphar. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 105. Julphar. Recent Developments/Updates
    Table 106. Bristol-Myers Squibb Company. Basic Information, Area Served and Competitors
    Table 107. Bristol-Myers Squibb Company. Major Business
    Table 108. Bristol-Myers Squibb Company. Genetic Obesity Drug Product and Services
    Table 109. Bristol-Myers Squibb Company. Genetic Obesity Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 110. Global Key Players of Genetic Obesity Drug Upstream (Raw Materials)
    Table 111. Genetic Obesity Drug Typical Customers
List of Figure
    Figure 1. Genetic Obesity Drug Picture
    Figure 2. World Genetic Obesity Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Genetic Obesity Drug Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Genetic Obesity Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Genetic Obesity Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Genetic Obesity Drug Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Genetic Obesity Drug Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Genetic Obesity Drug Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Genetic Obesity Drug Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Genetic Obesity Drug Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Genetic Obesity Drug Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Genetic Obesity Drug Revenue (2018-2029) & (USD Million)
    Figure 13. Genetic Obesity Drug Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Genetic Obesity Drug Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Genetic Obesity Drug Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Genetic Obesity Drug by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Genetic Obesity Drug Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Genetic Obesity Drug Markets in 2022
    Figure 27. United States VS China: Genetic Obesity Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Genetic Obesity Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Genetic Obesity Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Genetic Obesity Drug Market Size Market Share by Type in 2022
    Figure 31. Sibutramine
    Figure 32. Orlistat
    Figure 33. Sympathomimetic Drugs
    Figure 34. Receptors Antagonists
    Figure 35. Others
    Figure 36. World Genetic Obesity Drug Market Size Market Share by Type (2018-2029)
    Figure 37. World Genetic Obesity Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 38. World Genetic Obesity Drug Market Size Market Share by Application in 2022
    Figure 39. Hospitals Pharmacy
    Figure 40. Retail Pharmacy
    Figure 41. Online Pharmacy
    Figure 42. Others
    Figure 43. Genetic Obesity Drug Industrial Chain
    Figure 44. Methodology
    Figure 45. Research Process and Data Source

Companies Mentioned

Pfizer, Inc.
Sanofi.
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biocon.
Adocia
GlaxoSmithKline Plc.
Novo Nordisk A/S.
Oramed Pharmaceuticals, Inc
Wockhardt.
Eli Lilly and Company.
Merck & Co., Inc.
Julphar.
Bristol-Myers Squibb Company.